Overcoming immunotherapy resistance in NSCLC

Lancet Oncol. 2022 Feb;23(2):191-193. doi: 10.1016/S1470-2045(21)00711-7. Epub 2022 Jan 13.

Authors

Michael MacManus¹, Fiona Hegi-Johnson²

Affiliations

¹ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: Michael.macmanus@petermac.org.
² Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

PMID: 35033225
DOI: 10.1016/S1470-2045(21)00711-7

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Immunotherapy / adverse effects
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics